ホーム>>Signaling Pathways>> Stem Cell>> YAP>>GA-017

GA-017

カタログ番号GC65116

GA-017 は、強力かつ選択的な LATS1 および LATS2 (大型腫瘍抑制キナーゼ 1/2) 阻害剤であり、IC50 値はそれぞれ 4.10 および 3.92 nM です。 GA-017 は細胞増殖の活性化剤です。 GA-017 は、YAP/TAZ の活性化と核移行を促進します。 GA-017 は、3D 培養条件下で細胞増殖を促進します。 GA-017 は、マウス腸オルガノイドの ex vivo 形成を促進します。

Products are for research use only. Not for human use. We do not sell to patients.

GA-017 化学構造

Cas No.: 2351906-74-4

サイズ 価格 在庫数 個数
5mg
$198.00
在庫あり
10mg
$306.00
在庫あり
25mg
$558.00
在庫あり
50mg
$855.00
在庫あり
100mg
$1,350.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents

GA-017 is a potent and selective LATS1 and LATS2 (large tumor suppressor kinase 1/2) inhibitor, with IC50 values of 4.10 and 3.92 nM, respectively. GA-017 is an activator of cell proliferation. GA-017 promotes YAP/TAZ activation and nuclear translocation. GA-017 promotes cell growth under 3D culture conditions. GA-017 enhances the ex vivo formation of mouse intestinal organoids[1].

GA-017 suppresses the cell death of HUVECs and promotes their cell growth[1].GA-017 facilitates SKOV3 cell growth, with an EC50 of 3.51 ± 0.26 μM[1].GA-017 competitively inhibited LATS1 and 2 against ATP, with Ki (inhibition constant) values of 0.58 ± 0.11 and 0.25 ± 0.03 nM, respectively[1].

[1]. Aihara A, et al. Small molecule LATS kinase inhibitors block the Hippo signaling pathway and promote cell growth under 3D culture conditions. J Biol Chem. 2022 Apr;298(4):101779.

レビュー

Review for GA-017

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GA-017

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.